Argenx Bv

Argenx Bvba

Argen-X N.v.

Christophe Frederic Jerome Blanchetot

Johannes Joseph Wilhelmus De Haard

Torsten Dreier

Sebastian Paul Van Der Woning

Michael Saunders

Tine Skak-Nielsen

Malene Bertelsen

Birgitte Ursø

Khalil El Mazouari

Jurgen Del Favero

Alex Klarenbeek

Ikbel Achour

Johannes Joesph Wilhelmus De Haard

The present invention relates to multispecific antibodies, for example bispecific antibodies, and methods for the isolation or purification of the same. The antibodies of the invention comprise first and second heavy chain-light chain pairings wherein each pairing comprises a distinct selective recognition site including one or more amino acid residues contributed from the heavy chain and the light chain of the pairing. The first and second selective recognition sites differ by at least one amino acid residue and can be differentially bound by first and second selective recognition agents according to the methods of the invention. Such methods facilitate the production of antibody preparations enriched for multispecific antibodies having the correct functional heavy chain-light chain pairings.

Asymmetric multispecific antibodies

The present invention relates to antibodies and antigen binding fragments thereof which bind to the cytokine receptor IL-22R, particularly human IL-22R. The invention also relates to pharmaceutical compositions comprising said antibodies or antigen binding fragments thereof, and methods of treating psoriasis, psoriatic arthritis or atopic dermatitis.

Anti-IL-22R antibodies

Disclosed is an immune library obtained from a Camelid species containing at antibody chains belonging to at least 7 human germline antibody chains. The presence of a large number of human germline antibody chain families in the library contributes to the usefulness of the library in producing antibodies to human target antigens. The antibodies produced from the library have low inherent immunogenicity.

Highly diverse combinatorial antibody libraries

The invention relates to a platform technology for production of antigen binding polypeptides having specificity for a desired target antigen which is based on the conventional antibody repertoire of species in the family Camelidae, and to antigen binding polypeptides obtained using this technology platform. In particular, the invention provides an antigen binding polypeptide comprising a VH domain and a VL domain, wherein at least one hypervariable loop or complementarity determining region (CDR) in the VH domain or the VL domain is obtained from a VH or VL domain of a species in the family Camelidae.

Antigen binding polypeptides

Growing community of inventors

Gouda, Netherlands

Christophe Frederic Jerome Blanchetot